Opipramol is a well-[[tolerability|tolerated]] drug and is said to produce fewer [[side effect]]s than [[selective serotonin reuptake inhibitor]]s (SSRIs) and [[serotonin–norepinephrine reuptake inhibitor]] (SNRIs).

 


 
The frequently (≥1% to <10%) reported adverse reactions with opipramol especially at the beginning of the treatment include [[fatigue (medical)|fatigue]], [[dry mouth]], blocked nose, [[hypotension]], and orthostatic dysregulation.

 


 
The adverse reactions reported occasionally(≥0.1% to <1%) include [[dizziness]], [[stupor]], [[micturition]] disturbances, [[accommodation (eye)|accommodation disturbances]], [[tremor]], [[weight gain]], thirst, allergic skin reactions (rash, urticaria), abnormal [[ejaculation]], [[erectile dysfunction|erectile impotence]], [[constipation]], transient increases in liver enzyme activities, [[tachycardia]], and [[palpitation]]s.

 


 
Rarely (≥0.01% to <0.1%) reported adverse reaction includes excitation, headache, paresthesia especially in elderly patients, [[psychomotor agitation|restlessness]], [[sweating]], [[sleep disorder|sleep disturbances]], [[edema]], [[galactorrhea]], urine blockage, [[nausea]] and [[vomiting]], collapse conditions, stimulation conducting disturbances, intensification of present heart insufficiency, blood profile changes particularly [[leukopenia]], [[confusion]], [[delirium]], stomach complaints, taste disturbance, and [[ileus|paralytic ileus]] especially with sudden discontinuation of a longer-term high-dose therapy.

 


 
Very rarely (<0.01%) adverse reaction includes [[seizures]], [[motor disorder]], ([[akathisia]], [[dyskinesia]]), [[ataxia]], [[polyneuropathy]], [[glaucoma]], [[anxiety]], [[hair loss]], [[agranulocytosis]], severe liver dysfunction after long-term treatment, [[jaundice]], and chronic liver damage.

 

